Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

PR Newswire - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here

Two-Part Design Provides Optionality for Interim Analysis in First Half of 2024

Full Data Readout Expected in the Second Half of 2024

BOSTON, Sept. 15, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced dosing of the first patient in its two-part, Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, for the treatment of nonalcoholic steatohepatitis (NASH), at The Pinnacle Edinberg/South Texas Research Institute in Edinburg, Texas, under the supervision of Principal Investigator, Dr. David Ramirez.

Read more at prnewswire.com

Related Symbols

Symbol Last Chg %Chg
NRBO 2.36 +0.01 +0.43%
Neurobo Pharmaceuticals Inc

Most Popular News

Doctor holding money by IherPhoto via iStock 1
1 Under-$10 Stock Set to Surge as Much as 963% in 2026
Image of Jensen Huang by glen photo via Shutterstock 2
Nvidia CEO Jensen Huang Warns Investors That the AI Market Is Bigger Than They Realize With Over ‘One and a Half Million AI Models in the World’
Buy Button by Formatoriginal via Shutterstock 3
Wall Street’s Top Warren Buffett Dividend Stocks to Buy Now
A man in a dark-blue collared shirt looking out the window by Suzanne Tucker via Shutterstock 4
One of Wall Street’s Most Iconic Companies Is Warning of a ‘Blue-Collar Crisis’ in 2026. What That Means, and Why It Matters for You.
Words options trading written on a book by Vitalii Vodolazskyi via Shutterstock 5
Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot